Evidence map›Paper›PMID 36059463›Full record

ArticleFrontiers in immunology2022

Immunological signature of patients with thymic epithelial tumors and Good syndrome.

Anna Maria Malfitano, Vittoria D'Esposito, Pietro De Placido, Marianna Tortora, Margaret Ottaviano, Erica Pietroluongo, Rocco Morra, Brigitta Mucci, Fabiana Napolitano, Liliana Montella and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Anna Maria MalfitanoDepartment of Translational Medical Sciences, University "Federico II", Naples, Italy.
Vittoria D'EspositoResearch Unit (URT) Genomics of Diabetes, Institute of Experimental Endocrinology and Oncology, National Research Council, Naples, Italy.
Pietro De PlacidoDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Marianna TortoraDepartment of Translational Medical Sciences, University "Federico II", Naples, Italy.
Margaret OttavianoRare Tumors Coordinating Center of Campania Region (CRCTR), Naples, Italy.
Erica PietroluongoDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Rocco MorraDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Brigitta MucciDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Fabiana NapolitanoDepartment of Translational Medical Sciences, University "Federico II", Naples, Italy.
Liliana MontellaASL NA2 NORD, Oncology Operative Unit, "Santa Maria delle Grazie" Hospital, Pozzuoli, Italy.
Mario GiulianoDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Sabino De PlacidoDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Daniela TerraccianoDepartment of Translational Medical Sciences, University "Federico II", Naples, Italy.
Giovannella PalmieriRare Tumors Coordinating Center of Campania Region (CRCTR), Naples, Italy.
Pietro FormisanoDepartment of Translational Medical Sciences, University "Federico II", Naples, Italy.
Federico II University Hospital · ITRegione Campania · ITInstitute for Experimental Endocrinology and Oncology · ITNational Research Council · ITOspedale Santa Maria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Thymic epithelial tumors (TETs) are frequently accompanied by Good Syndrome (GS), a rare immunodeficiency, characterized by hypogammaglobulinemia and peripheral B cell lymphopenia. TETs can be also associated to other immunological disorders, both immunodeficiency and autoimmunity. Methods: In this study, we enrolled TET patients with GS to address differences between patients with or without associated autoimmune diseases (AD). We analyzed the immunophenotype from peripheral blood of these patients focusing on selected immune cell subsets (CD4+T cells, CD8+T cells, T regulatory cells, NK cells, B-cells, monocytes, eosinophils, basophils, neutrophils) and serum levels of cytokines, chemokines and growth factors. Results: We observed higher number of leucocytes, in particular lymphocytes, B lymphopenia and lower number of T regulatory cells in TET patients with associated AD compared to TET patients without AD. In the group of TET patients with AD, we also observed increased serum levels of IL-15, VEGF, IP-10, GM-CSF, IL-6, and MIP-1α. Thus, we identified considerable differences in the lymphocyte profiles of TET patients with and without ADs, in particular a reduction in the numbers of B lymphocytes and T-regulatory cells in the former, as well as differences in the serum levels of various immune modulators. Conclusions: Although the pathogenic mechanisms are still unclear, our results add new knowledge to better understand the disease, suggesting the need of surveilling the immunophenotype of TET patients to ameliorate their clinical management.

Indexed as

Autoimmune DiseasesLymphopeniaNeoplasms, Glandular and EpithelialPrimary Immunodeficiency DiseasesThymus NeoplasmsCD4-Positive T-LymphocytesHumansAutoimmune diseaseschemokinescytokinesgrowth factorsimmunophenotypethymic epithelial tumorsT regulatory cells

Identifiers

PMID36059463
PMCPMC9434000
OpenAlexW4292478687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.